Latest Breaking News On - Generating mimetic innate immune cells - Page 4 : comparemela.com

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.

Peter chooCytomed therapeutics limitedCytomed therapeuticsAgency for scienceChina national intellectual property administrationGenerating mimetic innate immune cellsPluripotent stem cellSpotlight growth

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology
baltimorestar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baltimorestar.com Daily Mail and Mail on Sunday newspapers.

Peter chooAgency for scienceCytomed therapeuticsChina national intellectual property administrationCytomed therapeutics limitedGenerating mimetic innate immune cellsPluripotent stem cellSpotlight growth

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.

Peter chooCytomed therapeuticsCytomed therapeutics limitedChina national intellectual property administrationAgency for scienceGenerating mimetic innate immune cellsPluripotent stem cellSpotlight growth

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology
nashvilleherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nashvilleherald.com Daily Mail and Mail on Sunday newspapers.

Chinese Patent Granted for CytoMed Therapeutics Licensed iPSC-Based Technology

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).

Peter chooCytomed therapeutics limitedCytomed therapeuticsExchange commissionAgency for scienceGenerating mimetic innate immune cellsPluripotent stemLicence agreementPrivate securities litigation reform actAmed therapeuticsThe companyProprietary technologiesImmune cellsIopharmaceutical companyCytomed therapeutics limitedPluripotent stem cell